Physicians' Academy for Cardiovascular Education

Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition

Meeting report with video, highlights and slides of a PACE-CME symposium held during ERA-EDTA 2018 in Copenhagen on the role of SGLT2 inhibition in Diabetic Kidney Disease.

Meeting Impression | Mechanisms and outcomes of SGLT2 inhibition in T2DM

May 25, 2018, Copenhagen, Denmark
May 25, 2018, Copenhagen, Denmark

Download the meeting impression of this PACE symposium during EDTA-ERA 2018, that explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

Summary | Addressing the remaining questions on SGLT2 and CKD: a review of new outcome trials

May 25, 2018 - Prof. Colin Baigent

This summary of the presentation by prof. Baigent compares three new trials on SGLT2 inhibition to address the question whether SGLT2 inhibitors have any value for patients with established CKD.

Summary | Understanding CKD and SGLT2-inhibition: what are the key mechanisms?

May 25, 2018 - Prof. Per-Henrik Groop

This summary of the presentation by prof. Groop illustrates potential underlying mechanisms of the CV and renal protection seen with SGLT2 inhibition.

Summary | What are the key lessons from the EMPA-REG OUTCOME trial?

May 25, 2018 - Prof. Christoph Wanner

This summary of the presentation by prof. Wanner illustrates key lessons from the EMPA-REG OUTCOME trial focusing on the effect of empagliflozin on renal and cardiovascular (CV) events.

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland
Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

Prof. Per-Henrik Groop explores the mechanisms and outcomes of SGLT2 inhibition in diabetic kidney disease.

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom
Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.

Prof Baigent discusses the key areas of uncertainty of treatment with SGLT2 inhibitors in patients with CKD and what ongoing trials will likely contribute to our understanding of this drug class.

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME
Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Prof. Wanner summarizes the key lessons from the EMPA-REG OUTCOME trial in patients with pre-existing CKD.

Slides: SGLT2 inhibition in kidney disease: What are the key lessons from the EMPA-REG OUTCOME trial?

Presentation Prof. Wanner

Slides (presentation) - May 25, 2018 - ERA-EDTA 2018, Copenhagen - Prof. Christoph Wanner, MD - Würzburg, Germany
This lecture by prof. Christoph Wanner was part of a CME accredited symposium: Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition held at ERA-EDTA 2018 in Copenhagen

Slides as educational service to PACE members and meeting participants

Slides: Understanding CKD & SGLT2 inhibition: What are the key mechanisms for benefit?

Presentation prof Groop

Slides (presentation) - June 27, 2018 - ERA-EDTA 2018, Copenhagen - Per-Henrik Groop, MD - Helsinki, Finland
This lecture by prof. Per-Henrik Groop was part of a CME accredited symposium: Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition held at ERA-EDTA 2018 in Copenhagen

Slides as educational service to PACE members and meeting participants

Slides: Addressing the remaining questions on SGLT2 & CKD: A review of new outcome trials

Presentation prof Baigent

Slides (presentation) - June 27, 2018 - ERA-EDTA 2018, Copenhagen - Prof Colin Baigent, MD - Oxford, UK
This lecture by prof. Colin Baigent part of a CME accredited symposium: Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition held at ERA-EDTA 2018 in Copenhagen

Slides as educational service to PACE members and meeting participants

Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition
Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition